Recruiting NCT04351347
The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Ivermectin.
- Who it may be relevant to
- Registry conditions: COVID. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinical Study Evaluating the Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
Overview
Efficacy of Ivermectin in larger doses in COVID-19 treatment
Detailed description
Clinical Study Evaluating the Efficacy of Ivermectin in higher doses in COVID-19 treatment
Interventions
- Drug Ivermectin
ivermectin
Primary outcome measures
- Number of patients with improvement or died [Time frame: 1 month]
Eligibility criteria
Inclusion criteria
- Patients with covid 19
Exclusion criteria
- Allergy or side effects to treatment
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Tanta University — Tanta
Identifiers
NCT: NCT04351347 · ivermecin covid